Our recent studies indicate that early postnatal treatment targeting the arachidonic acid metabolism pathway by using an SEH inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA) ameliorates hypertension in both maternal HF consumption-induced and prenatal dexamethasone-induced hypertension models [29,47]. This evidence concerns the gene EPHX2 and hypertensive disorder.